dulanermin + FOLFIRI

dulanermin + FOLFIRI is an investigational combination regimen for treating metastatic colorectal cancer and potentially other gastrointestinal cancers. The combination includes dulanermin, a recombinant soluble human Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL), and the chemotherapy regimen FOLFIRI (folinic acid/leucovorin, fluorouracil [5-FU], and irinotecan). Dulanermin activates apoptosis in cancer cells by binding to pro-apoptotic death receptors DR4 and DR5, initiating programmed cell death. FOLFIRI components: - Irinotecan: a topoisomerase I inhibitor, blocking DNA replication and leading to cell death. - Fluorouracil (5-FU): an antimetabolite interfering with DNA synthesis. - Folinic acid: potentiates 5-FU’s activity by stabilizing the 5-FU-thymidylate synthase complex. The regimen is administered intravenously and investigated primarily in metastatic colorectal cancer, especially previously treated patients. In clinical studies, the safety profile of dulanermin + FOLFIRI was similar to FOLFIRI alone; main adverse events included fatigue, anemia, diarrhea, nausea, stomatitis, and neutropenia. Tumor response rates were consistent with known results for FOLFIRI in this patient population[1][3][5].

Brand names

Camptosar (irinotecan as part of FOLFIRI)

Other names

FOLFIRI regimen plus dulanerminApo2L/TRAIL plus FOLFIRIdulanermin plus irinotecan/5FU/folinic acid